NEURO-BIOTECH'S SymPath® PROJECTED MARKET PENETRATION AND REVENUE ANALYSIS

Oct 06, 2010, 13:16 ET from Neuro-Biotech Corp.

BASEL, Switzerland, Oct 6 /PRNewswire-FirstCall/ - Neuro-Biotech Corporation (PINKSHEET: MRES) (OTCQB: MRES)

POTENTIAL MARKET AND INCOME BASED ON 1 TEST; THE SymPath®

The SymPath® test is part of the 12 tests that Neuro-Biotech has the mandate to produce and distribute.

A brief list of statistics:

According to the World Health Organization (WHO), 1 in every 4 people or 25% of individuals develops one or more mental disorders at some stage in their life. Mental illnesses are more common than cancer, diabetes or heart disease. These illnesses do not discriminate; they can affect men, women, and children, regardless of gender, race, ethnicity and socio-economic status. Mental health issues represent 5 out of 10 leading causes of disability worldwide; amounting to nearly one-third of the disability in the world. Mental illness ranks first among illnesses that cause disability in the United States, Canada, and Western Europe. It is predicted that by the year 2010, depression will be the leading cause of disability worldwide, not cancer, heart diseases, diabetes, or AIDS (according to the World Health Organization (WHO)).

THE HUMAN COST

Unfortunately, almost 3,000 people commit suicide every day in the world according to the WHO. For every person that succeeds in taking their life there are at least 20 more who try. Suicide is a huge but largely preventable public health problem, responsible for almost half of all violent deaths and resulting in almost one million fatalities every year. Estimates suggest the annual death rate could rise to 1.5 million by the year 2020. In 90% of suicides, mental illness is the attributing cause. Suicide is also one of the top three causes of death among people between the ages of 15 and 34 years old. (Ref: World Health Organization and ASHA International, an acronym for A Source of Hope for All touched by mental illness.)

ECONOMIC COST: Mental disorders cost billions of dollars just in the United States (US)!

Disorders have clear economic costs. While numbers alone cannot convey the distress accompanying mental disorders, the economic impact can be calculated. Sufferers and their families or caregivers often experience reduced productivity at home and in the workplace. These lost wages, combined with the possibility of catastrophic health care expenditures, can seriously affect the patient and their families' financial situation by creating or worsening poverty. (Ref: WHO and ASHA International)

Wherever the economic expenses of mental disorders have been studied, the figures are staggering. The most comprehensive set of estimates come from the US. Mental disorders cost the United States more than $150 billion each year for treatment, for the outlay of social services and disability payments made for patients, and for lost productivity and premature mortality. (Ref: WHO and ASHA International)

TILL TODAY, this economic burden has not been fully and effectively measured. This is because of the lack of quantitative data and difficulties in measuring and evaluating.

SymPath® IS THE ANSWER: WHY?

Firstly, SymPath® assists the medical profession in diagnosing patients, based on quantitative measurement, as precise as current cholesterol tests. SymPath® allows determining with accuracy the severity level of the patient's anxiety or depressive state. By using our product, and based on an objective quantified measure, the medical practitioner will now be able to state, rather than subjectively determining the diagnosis, as is currently the situation.

Furthermore SymPath® will eliminate the costly and highly inefficient trial and errors currently performed by physicians in prescribing their recommended remedy, which can waste time and resources of the medical staff, and cause further harm for patients. For instance, clients suffering from depression or stress related disorders will immediately be identified through Neuro-Biotech's SymPath® test.

No more guessing, medical professionals will not only obtain accurate results, they will be able to properly diagnose their patients and prescribe the appropriate therapeutic approach and continued follow up with their patients.

PROJECTED MARKET PENETRATION AND REVENUE

In United States alone, the health care sector includes more than 780,000 hospitals (Ref: First Research), clinics, doctor offices, emergency care units, nursing homes and social services providers. That figure includes 3059 Mental Health care institutions with 77 million people living in them. It would take 5,145 doctors? to meet their needs. Those 77 million people will need at least 1 test to evaluate their level, reducing by the fact the number of practitioners. (Ref: Kaiser State Health Facts, Office of Shortage Designation, Bureau of Health Professions, Health Resources and Services Administration (HRSA), data as of 9/30/08)

Now let say that the 780,000 health care centers order just one test per day each, it is relatively easy to make a simple calculation when the average selling price per test is around $50. Those figures are valid for the United States and only for the first test and we have 12 licenses!

The SymPath® has already been tested on several thousand people in the world with an accuracy of 98.8%.

For more information, do not hesitate to contact us by writing to info@neuro-agora.com and your request will be transferred to the appropriate persons and we will get back to you as soon as possible.

Contact:
Neuro-Biotech Corp.
Dr Claude Poulin
41 61 500 05 16
info@neuro-agora.com
www.neuro-biotechcorp.com

Forward Looking Statements
This release contains statements that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "expects," "intends," "may," "projects," "targets" and other similar language that is considered forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties and persons reading this release are cautioned that such statements are only predictions, and that the Company's actual future results or performance may be materially different. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events, or otherwise, could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

SOURCE Neuro-Biotech Corp.